Stock listing
gettex:3NK Alphamab Oncology Aktie
German listing (gettex) of Alphamab Oncology · home listing HKEX:9966
Follow Alphamab Oncology into a list and get an email when it puts out news.
Home listing price · HKEX:9966
$6.90 HKD +0.23 (+3.4%)
Close on Oct 16, 2026 · This listing has no price on 6ix; the price shown is the home listing's, HKEX:9966
- Day range
- $6.81 – $7.18 HKDOct 16, 2026
- Volume
- 1.04M sharesOct 16, 2026
- 52-week range
- $6.23 – $15.68 HKDLowest and highest trades, Oct 17, 2025 – Oct 16, 2026
Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| HKEX:9966 · Home | $6.90 HKD | +0.225 (+3.4%) | 1,037,000 | $6.81 | $7.18 | $6.81 | $6.675 | Close on Oct 16, 2026 |
| Frankfurt:3NK | €0.765 EUR | -0.020 (-2.5%) | — | €0.765 | €0.765 | €0.765 | €0.785 | Close on Oct 19, 2026 |
Daily closes
Last 3 months, Jul 16, 2026 – Oct 16, 2026 · HKEX:9966 · HKD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $6.90 | +0.225 | +3.4% | $6.81 | $7.18 | $6.81 | 1,037,000 | |
| $6.675 | -0.245 | -3.5% | $6.915 | $6.915 | $6.62 | 2,168,000 | |
| $6.92 | -0.125 | -1.8% | $7.045 | $7.055 | $6.73 | 1,360,000 | |
| $7.045 | -0.135 | -1.9% | $7.03 | $7.115 | $6.815 | 945,000 | |
| $7.18 | -0.175 | -2.4% | $7.40 | $7.50 | $7.145 | 871,000 | |
| $7.355 | -0.185 | -2.5% | $7.515 | $7.515 | $7.16 | 1,543,000 | |
| $7.54 | -0.545 | -6.7% | $8.055 | $8.055 | $7.48 | 1,940,000 | |
| $8.085 | -0.295 | -3.5% | $8.355 | $8.355 | $8.035 | 549,000 | |
| $8.38 | -0.02 | -0.2% | $8.40 | $8.635 | $8.26 | 479,000 | |
| $8.40 | +0.095 | +1.1% | $8.35 | $8.49 | $8.10 | 518,000 | |
| $8.305 | -0.145 | -1.7% | $8.16 | $8.415 | $7.825 | 1,096,257 | |
| $8.45 | +0.40 | +5.0% | $8.10 | $8.49 | $8.10 | 1,433,000 | |
| $8.05 | +0.05 | +0.6% | $8.075 | $8.22 | $7.96 | 1,301,000 | |
| $8.00 | -0.335 | -4.0% | $8.345 | $8.345 | $7.90 | 645,258 | |
| $8.335 | +0.015 | +0.2% | $8.205 | $8.46 | $8.115 | 629,000 | |
| $8.32 | -0.24 | -2.8% | $8.26 | $8.45 | $8.215 | 664,000 | |
| $8.56 | +0.455 | +5.6% | $8.015 | $8.62 | $8.015 | 1,136,500 | |
| $8.105 | +0.025 | +0.3% | $8.13 | $8.33 | $7.91 | 1,066,000 | |
| $8.08 | +0.33 | +4.3% | $7.775 | $8.23 | $7.575 | 1,871,000 | |
| $7.75 | +0.08 | +1.0% | $7.865 | $7.995 | $7.60 | 1,396,000 | |
| $7.67 | -0.055 | -0.7% | $7.875 | $7.875 | $7.605 | 610,472 | |
| $7.725 | -0.16 | -2.0% | $7.805 | $7.805 | $7.56 | 794,528 | |
| $7.885 | -0.145 | -1.8% | $8.03 | $8.03 | $7.83 | 332,000 | |
| $8.03 | +0.06 | +0.8% | $7.965 | $8.075 | $7.805 | 721,258 | |
| $7.97 | -0.36 | -4.3% | $8.115 | $8.125 | $7.825 | 1,226,000 | |
| $8.33 | -0.12 | -1.4% | $8.305 | $8.40 | $8.12 | 841,000 | |
| $8.45 | +0.14 | +1.7% | $8.32 | $8.49 | $8.255 | 976,000 | |
| $8.31 | -0.295 | -3.4% | $8.505 | $8.56 | $8.31 | 1,182,000 | |
| $8.605 | -0.165 | -1.9% | $8.735 | $8.925 | $8.55 | 1,001,000 | |
| $8.77 | -0.09 | -1.0% | $8.90 | $9.15 | $8.735 | 434,000 | |
| $8.86 | +0.29 | +3.4% | $8.615 | $8.90 | $8.515 | 1,119,000 | |
| $8.57 | +0.14 | +1.7% | $8.45 | $8.82 | $8.30 | 1,502,000 | |
| $8.43 | -0.535 | -6.0% | $9.25 | $9.265 | $8.415 | 1,446,000 | |
| $8.965 | +0.295 | +3.4% | $8.78 | $9.385 | $8.40 | 3,070,500 | |
| $8.67 | -0.445 | -4.9% | $9.01 | $9.13 | $8.49 | 1,824,000 | |
| $9.115 | +0.66 | +7.8% | $8.55 | $9.20 | $8.55 | 2,630,000 | |
| $8.455 | +0.325 | +4.0% | $8.23 | $8.86 | $8.23 | 2,481,000 | |
| $8.13 | +0.005 | +0.1% | $8.23 | $8.28 | $8.00 | 776,000 | |
| $8.125 | -0.055 | -0.7% | $8.185 | $8.19 | $8.03 | 599,000 | |
| $8.18 | -0.165 | -2.0% | $8.315 | $8.32 | $8.05 | 887,000 | |
| $8.345 | +0.21 | +2.6% | $8.20 | $8.82 | $8.20 | 1,959,000 | |
| $8.135 | +0.07 | +0.9% | $8.015 | $8.45 | $8.00 | 1,382,000 | |
| $8.065 | -0.285 | -3.4% | $8.11 | $8.30 | $8.00 | 650,000 | |
| $8.35 | +0.20 | +2.5% | $8.15 | $8.35 | $7.96 | 1,057,000 | |
| $8.15 | -0.30 | -3.6% | $8.325 | $8.375 | $8.08 | 949,000 | |
| $8.45 | +0.01 | +0.1% | $8.36 | $8.555 | $8.26 | 700,000 | |
| $8.44 | -0.115 | -1.3% | $8.425 | $8.53 | $8.335 | 476,000 | |
| $8.555 | +0.065 | +0.8% | $8.46 | $8.895 | $8.46 | 1,370,000 | |
| $8.49 | +0.47 | +5.9% | $8.17 | $8.50 | $8.055 | 1,678,000 | |
| $8.02 | +0.25 | +3.2% | $7.775 | $8.12 | $7.775 | 713,000 | |
| $7.77 | -0.125 | -1.6% | $7.81 | $7.92 | $7.60 | 654,000 | |
| $7.895 | +0.235 | +3.1% | $7.895 | $8.06 | $7.84 | 693,000 | |
| $7.66 | +0.26 | +3.5% | $7.80 | $8.35 | $7.60 | 2,607,000 | |
| $7.40 | -0.07 | -0.9% | $7.56 | $7.56 | $7.28 | 1,164,000 | |
| $7.47 | -0.11 | -1.5% | $7.61 | $7.69 | $7.37 | 599,000 | |
| $7.58 | +0.02 | +0.3% | $7.56 | $7.63 | $7.38 | 885,000 | |
| $7.56 | -0.38 | -4.8% | $7.94 | $7.94 | $7.44 | 897,000 | |
| $7.94 | -0.06 | -0.7% | $7.84 | $8.08 | $7.69 | 985,000 | |
| $8.00 | +0.04 | +0.5% | $7.96 | $8.17 | $7.78 | 812,000 | |
| $7.96 | +0.35 | +4.6% | $7.56 | $8.07 | $7.48 | 940,000 | |
| $7.61 | +0.03 | +0.4% | $7.57 | $7.84 | $7.41 | 882,000 | |
| $7.58 | +0.28 | +3.8% | $7.21 | $7.80 | $7.20 | 1,553,000 | |
| $7.30 | -0.05 | -0.7% | $7.30 | $7.40 | $6.96 | 1,016,000 | |
| $7.35 | +0.40 | +5.8% | $7.01 | $7.50 | $7.01 | 1,659,000 | |
| $6.95 | -0.66 | -8.7% | $7.51 | $7.55 | $6.79 | 2,672,000 | |
| $7.61 | -0.31 | -3.9% | $7.97 | $7.97 | $7.56 | 886,000 |
- Ticker
- gettex:3NK
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- gettex
- Currency
- EUR
What changed lately
Latest news release · Oct 15, 2026
Next Day Disclosure Return
Latest news
Next Day Disclosure Return
Oct 15, 2026
Closed $6.90 (+3.4%) on Oct 16, 2026
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2026
Oct 5, 2026
Closed $8.38 (-0.2%) on Oct 6, 2026
2026 Interim report
Sep 24, 2026
Closed $8.34 (+0.2%) on Sep 25, 2026
2026 ASCO Preview | Alphamab Oncology to Present Clinical Data of TROP2/HER3 Bispecific ADC JSKN016 for HER2-Negative Breast Cancer
Apr 22, 2026
Closed $11.47 (-2.8%) on Apr 23, 2026
2026 ASCO Preview | Results from Phase III Study of Anbenitamab (KN026) Combined with HB1801 in Neoadjuvant Treatment for Breast Cancer Selected for LBA Oral Presentation
Apr 22, 2026
Closed $11.80 (+5.6%) on Apr 22, 2026
Alphamab Oncology Announces the Phase III Clinical Study of Anbenitamab (KN026) Combined with HB1801 as Neoadjuvant Treatment for Breast Cancer Has Met the Primary Endpoint
Apr 1, 2026
Closed $9.04 (-0.1%) on Apr 2, 2026
Alphamab Oncology Reports Full Year 2025 Financial Results and Business Highlights
Mar 26, 2026
Closed $7.74 (-4.2%) on Mar 26, 2026
Alphamab Oncology Announces the First Patient Dosed in a Phase III Clinical Study of Anbenitamab (KN026) Combined with HB1801 and Chemotherapy as Adjuvant Treatment of Breast Cancer
Mar 23, 2026
Closed $8.16 (+1.5%) on Mar 24, 2026
Alphamab Oncology Announces the First Patient Dosed in a Phase III Clinical Study for Triple-Negative Breast Cancer of TROP2/HER3 Bispecific ADC JSKN016
Mar 19, 2026
Closed $8.35 (-1.4%) on Mar 20, 2026
Alphamab Oncology Appoints Mr. Fei Wang as Chief Financial Officer
Mar 18, 2026
Closed $8.47 (-7.0%) on Mar 19, 2026
Alphamab Oncology on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 25 in the last 12 months · 48 in all · newest Oct 15, 2026 · oldest 2020
Where Alphamab Oncology is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| HKEX:9966 康寧傑瑞製藥 · Home listing | HKEX | Hong Kong | HKD |
| LS Exchange:A2PWDV | LS Exchange | Germany | EUR |
| Lang & Schwarz:A2PWDV | Lang & Schwarz | Germany | EUR |
| gettex:3NK · This page | gettex | Germany | EUR |
| Dusseldorf:3NK | Dusseldorf | Germany | EUR |
| Frankfurt:3NK | Frankfurt | Germany | EUR |
| Munich:3NK | Munich | Germany | EUR |
| OTC:ALMOF | OTC | United States | USD |
| Stuttgart:3NK | Stuttgart | Germany | EUR |
| Tradegate:3NK | Tradegate | Germany | EUR |
Log in to ask 6ix AI your own questions about Alphamab Oncology.